MedTrace Logo

Topical Cetirizine in Androgenetic Alopecia in Females

NCT04481412 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 66

Last updated 2023-02-08

No results posted yet for this study

Summary

Cetirizine is a safe and selective, second-generation histamine H1 receptor antagonist, widely used in daily practice. A study showed that cetirizine causes a significant reduction in both the inflammatory cell infiltrate and PGD2 production. A pilot study on topical cetirizine showed that cetirizine increased total hair density, terminal hair density and diameter. Also, its lower potential side effects if compared with other drugs commonly used for AGA, as minoxidil, can promote a wider use and better compliance of cetirizine in the future for the treatment of AGA. Combinations of therapies are likely to be more efficacious than single treatments.

Treatments to clinically improve scalp hair density and reduce mid-pattern thinning leading to improved scalp coverage are highly important for the affected women. On the basis of the above evidence and lacking studies that confirm the effectiveness of cetirizine in AGA treatment, the aim of this study is to evaluate the efficacy and tolerability of topical cetirizine in female patients with AGA.

Conditions

Interventions

DRUG

Topical cetirizine

Topical cetirizine 1% spray that will be prepared at Faculty of Pharmacy, Cairo University and will be applied once daily.

DRUG

Placebo

96% ethanol that will be applied once daily.

DRUG

Topical minoxidil

Topical Minoxidil 5% that will be applied once daily.

Sponsors & Collaborators

  • Cairo University

    lead OTHER

Principal Investigators

  • Maggie Abbassi, PhD · Faculty of Pharmacy, Cairo University

  • Hanan Nada, PhD · Cairo University

  • Samar Farid, PhD · Faculty of Pharmacy, Cairo University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
50 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-25
Primary Completion
2021-11-30
Completion
2021-11-30

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04481412 on ClinicalTrials.gov